Literature DB >> 10520713

Oncological applications of FDG PET imaging.

D Delbeke1.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10520713

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  25 in total

Review 1.  PET/CT: a new imaging technology in nuclear medicine.

Authors:  Heiko Schöder; Yusuf E Erdi; Steven M Larson; Henry W D Yeung
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-05       Impact factor: 9.236

2.  FDG-PET: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Cumali Aktolun; Richard P Baum; Angelika Bishof-Delaloye; John Buscombe; Jean François Chatal; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12       Impact factor: 9.236

3.  [¹⁸F]Fluorodeoxyglucose positron emission tomography-guided therapy in metastatic adrenocortical carcinoma: an illustrative case.

Authors:  Hubert H Chuang; Ferhat Deniz; Kanishka Sircar; Camilo Jimenez; Carlos Rubin De Celis; Christopher G Wood; Mouhammed Amir Habra
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

4.  ¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.

Authors:  Alexandre Cochet; Inna Dygai-Cochet; Jean-Marc Riedinger; Olivier Humbert; Alina Berriolo-Riedinger; Michel Toubeau; Séverine Guiu; Charles Coutant; Bruno Coudert; Pierre Fumoleau; François Brunotte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-07       Impact factor: 9.236

5.  ¹⁸F-FDG PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with suspected cardiac endocarditis.

Authors:  Rachele Bonfiglioli; Cristina Nanni; Joshua James Morigi; Maddalena Graziosi; Filippo Trapani; Michele Bartoletti; Fabio Tumietto; Valentina Ambrosini; Alice Ferretti; Domenico Rubello; Claudio Rapezzi; Pier Luigi Viale; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-08       Impact factor: 9.236

6.  Initial experience with FDG-PET/CT in the evaluation of breast cancer.

Authors:  Mitsuaki Tatsumi; Christian Cohade; Karen A Mourtzikos; Elliot K Fishman; Richard L Wahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-29       Impact factor: 9.236

7.  Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.

Authors:  Shawn M Hillier; Kevin P Maresca; Frank J Femia; John C Marquis; Catherine A Foss; Nghi Nguyen; Craig N Zimmerman; John A Barrett; William C Eckelman; Martin G Pomper; John L Joyal; John W Babich
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

8.  Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine.

Authors:  Alexander Becherer; Georgios Karanikas; Monica Szabó; Georg Zettinig; Susanne Asenbaum; Christine Marosi; Christine Henk; Patrick Wunderbaldinger; Thomas Czech; Wolfgang Wadsak; Kurt Kletter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-23       Impact factor: 9.236

9.  Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin's lymphoma: comparison with serum soluble interleukin-2 receptor values.

Authors:  Mitsuaki Tatsumi; Hiroyuki Sugahara; Ichiro Higuchi; Hiroki Fukunaga; Hironobu Nakamura; Yuzuru Kanakura; Jun Hatazawa
Journal:  Int J Clin Oncol       Date:  2009-04-24       Impact factor: 3.402

10.  Reproducibility of semi-quantitative parameters in FDG-PET using two different PET scanners: influence of attenuation correction method and examination interval.

Authors:  Tomohito Kamibayashi; Tatsuro Tsuchida; Yoshiki Demura; Tetsuya Tsujikawa; Hidehiko Okazawa; Takashi Kudoh; Hirohiko Kimura
Journal:  Mol Imaging Biol       Date:  2008-04-12       Impact factor: 3.488
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.